Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.


Journal

Drug metabolism and bioanalysis letters
ISSN: 2949-6829
Titre abrégé: Drug Metab Bioanal Lett
Pays: United Arab Emirates
ID NLM: 9918418288306676

Informations de publication

Date de publication:
2022
Historique:
received: 15 09 2021
revised: 16 11 2021
accepted: 17 12 2021
pubmed: 21 1 2022
medline: 19 8 2022
entrez: 20 1 2022
Statut: ppublish

Résumé

Genetic polymorphism of cytochrome P450 (CYP) contributes to variability in drug metabolism, clearance, and response. This study aimed to investigate the functional and molecular basis for altered ligand binding and catalysis in CYP2D6*14A and CYP2D6*14B, two unique alleles common in the Asian population. CYP proteins expressed in Escherichia coli were studied using the substrate 3-cyano-7- ethoxycoumarin (CEC) and inhibitor probes (quinidine, fluoxetine, paroxetine, terbinafine) in the enzyme assay. Computer modelling was additionally used to create three-dimensional structures of the CYP2D6*14 variants. Kinetics data indicated significantly reduced intrinsic clearance in CYP2D6*14 variants, suggesting that P34S, G169R, R296C, and S486T substitutions worked cooperatively to alter the conformation of the active site that negatively impacted the deethylase activity of CYP2D6. For the inhibition studies, IC50 values decreased in quinidine, paroxetine, and terbinafine but increased in fluoxetine, suggesting a varied ligand-specific susceptibility to inhibition. Molecular docking further demonstrated the role of P34S and R296C in altering access channel dimensions, thereby affecting ligand access and binding and subsequently resulting in varied inhibition potencies. In summary, the differential selectivity of CYP2D6*14 variants for the ligands (substrate and inhibitor) was governed by the alteration of the active site and access channel architecture induced by the natural mutations found in the alleles.

Sections du résumé

BACKGROUND
Genetic polymorphism of cytochrome P450 (CYP) contributes to variability in drug metabolism, clearance, and response. This study aimed to investigate the functional and molecular basis for altered ligand binding and catalysis in CYP2D6*14A and CYP2D6*14B, two unique alleles common in the Asian population.
METHODS
CYP proteins expressed in Escherichia coli were studied using the substrate 3-cyano-7- ethoxycoumarin (CEC) and inhibitor probes (quinidine, fluoxetine, paroxetine, terbinafine) in the enzyme assay. Computer modelling was additionally used to create three-dimensional structures of the CYP2D6*14 variants.
RESULTS
Kinetics data indicated significantly reduced intrinsic clearance in CYP2D6*14 variants, suggesting that P34S, G169R, R296C, and S486T substitutions worked cooperatively to alter the conformation of the active site that negatively impacted the deethylase activity of CYP2D6. For the inhibition studies, IC50 values decreased in quinidine, paroxetine, and terbinafine but increased in fluoxetine, suggesting a varied ligand-specific susceptibility to inhibition. Molecular docking further demonstrated the role of P34S and R296C in altering access channel dimensions, thereby affecting ligand access and binding and subsequently resulting in varied inhibition potencies.
CONCLUSION
In summary, the differential selectivity of CYP2D6*14 variants for the ligands (substrate and inhibitor) was governed by the alteration of the active site and access channel architecture induced by the natural mutations found in the alleles.

Identifiants

pubmed: 35049443
pii: DML-EPUB-120165
doi: 10.2174/1872312815666220113125232
doi:

Substances chimiques

Ligands 0
Fluoxetine 01K63SUP8D
Paroxetine 41VRH5220H
Cytochrome P-450 Enzyme System 9035-51-2
Cytochrome P-450 CYP2D6 EC 1.14.14.1
Terbinafine G7RIW8S0XP
Quinidine ITX08688JL

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

51-63

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Amelia Nathania Dong (AN)

School of Pharmacy, Monash University Malaysia, Selangor, Malaysia.

Nafees Ahemad (N)

School of Pharmacy, Monash University Malaysia, Selangor, Malaysia.

Yan Pan (Y)

Department of Biomedical Science, University of Nottingham, Malaysia Campus, Semenyih, Selangor, Malaysia.

Uma Devi Palanisamy (UD)

Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Selangor, Malaysia.

Beow Chin Yiap (BC)

School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.

Chin Eng Ong (CE)

School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.

Articles similaires

Animals Hemiptera Insect Proteins Phylogeny Insecticides

Prevalence and implications of fragile X premutation screening in Thailand.

Areerat Hnoonual, Sunita Kaewfai, Chanin Limwongse et al.
1.00
Humans Fragile X Mental Retardation Protein Thailand Male Female
Fucosyltransferases Drug Repositioning Molecular Docking Simulation Molecular Dynamics Simulation Humans
Saccharomyces cerevisiae Aldehydes Biotransformation Flavoring Agents Lipoxygenase

Classifications MeSH